{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:44:57Z","timestamp":1785887097759,"version":"3.56.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study was conducted to investigate the clinical response, safety, and pharmacokinetic (PK) profile of eravacycline-based combination therapies in patients with pulmonary infections caused by carbapenem-resistant\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (CRAB).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective observational case series was conducted on patients with CRAB pneumonia treated at Fujian Medical University Union Hospital between February 2024 and August 2025. Prior to treatment, eravacycline minimum inhibitory concentration were determined. Patients received eravacycline-based combination therapy according to their susceptibility results. Data on clinical responses, microbiological clearance, adverse events, and 28-day all-cause mortality were collected. Eravacycline blood concentrations were measured in a subset of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two patients with CRAB pneumonia (21 with ventilator-associated pneumonia) were enrolled; all had a Clinical Pulmonary Infection Score &amp;gt;6. The mean Acute Physiology and Chronic Health Evaluation II (APACHE II) scores and the Sequential Organ Failure Assessment (SOFA) scores were 13.77 and 6.23, respectively. All CRAB isolates were susceptible to eravacycline (ChiCAST breakpoint \u22641\u00a0mg\/L). The clinical response rate, microbiological clearance rate, and 28-day mortality were 72.7%, 86.4%, and 13.6%, respectively. Two patients exhibited hypofibrinogenemia, considered an adverse drug reaction related to eravacycline. No associated bleeding events or other adverse events were observed. Nonresponders had significantly higher SOFA and APACHE II scores than clinical responders. Eravacycline PK was assessed in 14 patients and showed considerable interindividual variability. Among the PK parameters, C\n                      <jats:sub>max<\/jats:sub>\n                      correlated significantly with clinical response (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.729,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The preliminary findings of this prospective observational case series indicate that individualized eravacycline-based combination regimens are associated with promising clinical outcomes and microbiological clearance, with good tolerability and a low incidence of adverse events. Additionally, initial blood concentration data provide a reference for future exploration of PK\/PD targets in CRAB pneumonia. However, due to the small sample size and limited statistical power, these findings should be considered preliminary and require validation in larger prospective cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1796494","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:56:13Z","timestamp":1778129773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical experience with eravacycline-based combination therapy for carbapenem-resistant Acinetobacter baumannii pneumonia: a prospective observational case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Fujian Medical University Union Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.2366","article-title":"Evaluation of eravacycline: a novel fluorocycline","volume":"40","author":"Alosaimy","year":"","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"","journal-title":"Open Forum Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0047922","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fmed.2022.772372","article-title":"Polymyxin B\/Tigecycline combination vs. polymyxin B or tigecycline alone for the treatment of hospital-acquired pneumonia caused by carbapenem-resistant enterobacteriaceae or carbapenem-resistant Acinetobacter baumannii","volume":"9","author":"Chang","year":"2022","journal-title":"Front. Med."},{"key":"B5","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/aac.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3760\/cma.j.cn114452-20250211-00074","article-title":"Specifications for antimicrobial susceptibility testing of eravacycline(2025)","volume":"48","author":"Ecast","year":"2025","journal-title":"Chin. J. Laboratory Med."},{"key":"B8","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters\n          \n          \n          2025"},{"key":"B9","article-title":"Xerava (eravacycline) susceptibility interpretive criteria for enterobacteriaceae","year":"2025","journal-title":"Food Drug Adm"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40265-024-02104-6","article-title":"Treatment approaches for carbapenem-resistant Acinetobacter baumannii infections","volume":"85","author":"Iovleva","year":"2025","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/phar.2908","article-title":"Combination eravacycline therapy for ventilator\u2010associated pneumonia due to carbapenem\u2010resistant Acinetobacter baumannii in patients with COVID\u201019: a case series","volume":"44","author":"Jackson","year":"2024","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0106524","DOI":"10.1128\/aac.01065-24","article-title":"Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK\/PD","volume":"69","author":"Ji","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.13507\/j.issn.1674-3474.2024.10.015","article-title":"Observational Study on the efficacy of eravacycline in treating carbapenem-resistant Acinetobacter baumannii pulmonary infections Chinese journal of practical diagnosis and therapy","author":"Jia","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0150642","DOI":"10.1371\/journal.pone.0150642","article-title":"Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0106324","DOI":"10.1128\/aac.01063-24","article-title":"Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations","volume":"69","author":"Kubin","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"908.e901","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Liang","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.3760\/cma.j.cn112137-20240517-01132","article-title":"Comparison of efficacy and safety between elacycline and polymyxin for complicated intra-abdominal infections caused by multidrug-resistant bacteria","volume":"104","author":"Lu","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus Colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective Study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J. Crit. Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/cmr.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"B21","volume-title":"Antimicrobial resistance threats in the United States, 2021-2022","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A real-world assessment of clinical outcomes and safety of eravacycline: a novel fluorocycline","volume":"9","author":"Van Hise","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"B27","volume-title":"The use of the WHO-UMC system for standardised case causality assessment [Online]","year":"2013"},{"key":"B28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14740338.2024.2392865","article-title":"Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database","volume":"24","author":"Xiong","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.16718\/j.1009-7708.2025.06.002","article-title":"2024 CHINET China bacterial resistance surveillance","volume":"25","author":"Yan","year":"2025","journal-title":"Chin. J. Infect. Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","article-title":"Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli","volume":"56","author":"Zeng","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B31","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","article-title":"In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3760\/cma.j.issn.0578-1426.2014.12.015","article-title":"Interpretation of the expert consensus on the diagnosis and treatment of multidrug-resistant gram-negative bacterial infections","volume":"53","author":"Zhou","year":"2014","journal-title":"Chin. J. Intern. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-019-0300-3","article-title":"Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii","volume":"20","author":"Zhou","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2147\/idr.S396910","article-title":"Antibacterial activity of eravacycline against carbapenem-resistant gram-negative isolates in China: an in vitro Study","volume":"16","author":"Zou","year":"2023","journal-title":"Infect. Drug Resist"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1796494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:56:19Z","timestamp":1778129779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1796494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1796494"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1796494","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1796494"}}